中华心血管病杂志
中華心血管病雜誌
중화심혈관병잡지
Chinese Journal of Cardiology
2014年
3期
247-253
,共7页
冯雪茹%张婧薇%刘梅林%李雪迎
馮雪茹%張婧薇%劉梅林%李雪迎
풍설여%장청미%류매림%리설영
动脉粥样硬化%颈动脉狭窄%治疗结果%瑞舒伐他汀
動脈粥樣硬化%頸動脈狹窄%治療結果%瑞舒伐他汀
동맥죽양경화%경동맥협착%치료결과%서서벌타정
Atherosclerosis%Carotid stenosis%Treatment outcome%Rosuvastatin
目的 评价瑞舒伐他汀对中国颈动脉粥样硬化患者的颈动脉内中膜厚度(IMT)的影响及其安全性.方法 采用Cochrane系统评价方法,计算机检索美国Pubmed、荷兰EMBase、美国CENTRAL、中国生物医学文献数据库、中国知网、万方数据资源系统,末次检索日期为2013年1月31日.纳入中英文的瑞舒伐他汀与安慰剂或其他他汀类药物比较颈动脉IMT的中国人群研究.采用RevMan 5.0软件进行荟萃分析.结果 共纳入文献28篇,包括1 392例患者.瑞舒伐他汀与安慰剂和(或)空白对照对比的分析显示,随访6～8个月和12个月时,瑞舒伐他汀组与对照组IMT差值分别为0.31 mm(95％CI0.14～0.49,P＜0.01)和0.16 mm(95％CI0.05 ～0.27,P=0.005)；汇总后的IMT差值为0.28 mm(95％ CI0.14 ～0.42,P＜0.01).与其他他汀类药物比较,瑞舒伐他汀组与其他他汀类药物组的IMT均数差值为0.06 mm(95％CI0.04～0.08,P＜0.01).肝酶、肌酶升高和肌痛的发生率分别为2.30％(19/825)、0.73％(6/825)和0.61％ (5/825).结论 瑞舒伐他汀降低中国动脉粥样硬化患者的颈动脉IMT,安全性良好.
目的 評價瑞舒伐他汀對中國頸動脈粥樣硬化患者的頸動脈內中膜厚度(IMT)的影響及其安全性.方法 採用Cochrane繫統評價方法,計算機檢索美國Pubmed、荷蘭EMBase、美國CENTRAL、中國生物醫學文獻數據庫、中國知網、萬方數據資源繫統,末次檢索日期為2013年1月31日.納入中英文的瑞舒伐他汀與安慰劑或其他他汀類藥物比較頸動脈IMT的中國人群研究.採用RevMan 5.0軟件進行薈萃分析.結果 共納入文獻28篇,包括1 392例患者.瑞舒伐他汀與安慰劑和(或)空白對照對比的分析顯示,隨訪6～8箇月和12箇月時,瑞舒伐他汀組與對照組IMT差值分彆為0.31 mm(95％CI0.14～0.49,P＜0.01)和0.16 mm(95％CI0.05 ～0.27,P=0.005)；彙總後的IMT差值為0.28 mm(95％ CI0.14 ～0.42,P＜0.01).與其他他汀類藥物比較,瑞舒伐他汀組與其他他汀類藥物組的IMT均數差值為0.06 mm(95％CI0.04～0.08,P＜0.01).肝酶、肌酶升高和肌痛的髮生率分彆為2.30％(19/825)、0.73％(6/825)和0.61％ (5/825).結論 瑞舒伐他汀降低中國動脈粥樣硬化患者的頸動脈IMT,安全性良好.
목적 평개서서벌타정대중국경동맥죽양경화환자적경동맥내중막후도(IMT)적영향급기안전성.방법 채용Cochrane계통평개방법,계산궤검색미국Pubmed、하란EMBase、미국CENTRAL、중국생물의학문헌수거고、중국지망、만방수거자원계통,말차검색일기위2013년1월31일.납입중영문적서서벌타정여안위제혹기타타정류약물비교경동맥IMT적중국인군연구.채용RevMan 5.0연건진행회췌분석.결과 공납입문헌28편,포괄1 392례환자.서서벌타정여안위제화(혹)공백대조대비적분석현시,수방6～8개월화12개월시,서서벌타정조여대조조IMT차치분별위0.31 mm(95％CI0.14～0.49,P＜0.01)화0.16 mm(95％CI0.05 ～0.27,P=0.005)；회총후적IMT차치위0.28 mm(95％ CI0.14 ～0.42,P＜0.01).여기타타정류약물비교,서서벌타정조여기타타정류약물조적IMT균수차치위0.06 mm(95％CI0.04～0.08,P＜0.01).간매、기매승고화기통적발생솔분별위2.30％(19/825)、0.73％(6/825)화0.61％ (5/825).결론 서서벌타정강저중국동맥죽양경화환자적경동맥IMT,안전성량호.
Objective To evaluate the efficacy and safety of rosuvastatin in Chinese patients with carotid atherosclerosis.Method A systematic search of Pubmed,EMBase,CENTRAL,CBMdisc,CNKI and WANFANG databases up to January 2013 was performed to identify studies comparing rosuvastatin with a placebo or other statins on carotid intima-medial thickness (IMT) with a minimum follow-up of 6 months in Chinese patients.Meta-analysis was performed by using RevMan 5.0 software after the strict evaluation of the methodological quality of the included studies independently by two reviewers.Results Twenty-eight studies involving 1 392 individuals were included in this review.The pooled weighted mean difference (WMD) between rosuvastatin and placebo or control on IMT was 0.28 mm (95％ CI 0.14-0.42,P ＜0.01),with 0.31 mm (95％CI0.14-0.49,P＜0.01) on6-8 months and0.16 mm (95％CI0.05-0.27,P=0.005) on 12 months,respectively.Analysis on studies in core journals showed the WMD between rosuvastatin and placebo or control on IMT was 0.18 mm (95％ CI 0.09-0.27,P ＜ 0.01).The WMD between rosuvastatin and other statins on IMT was 0.06 mm (95％ CI0.04-0.08,P ＜ 0.01).The WMD between rosuvastatin and placebo or control on plaque score was 0.89 (95％ CI 0.78-0.99,P ＜ 0.01).The WMD between rosuvastatin and placebo or control on plaque area was 1.46 (95％ CI 0.67-2.25,P ＜0.01).Reports of adverse effect were elevated liver enzyme (2.30％,19/825),elevated muscle enzyme (0.73％,6/825),muscle aches (0.61％,5/825).Conclusions Rosuvastatin therapy is effective and safe to decrease IMT in Chinese patients with carotid atherosclerosis.
